Immunological responses induced by a DNA vaccine expressing RON4 and by immunogenic recombinant protein RON4 failed to protect mice against chronic toxoplasmosis

Vaccine

Volumn 29, Issue 48, 2011, Pages 8838-8846

  Rashid, Imran ^a   Hedhli, Dorsaf ^a   Moiré, Nathalie ^a   Pierre, Josette ^a   Debierre Grockiego, Françoise ^a   Dimier Poisson, Isabelle ^a   Mévélec, Marie Noëlle ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

Immunity; RON4; Toxplasma gondii; Vaccine

Indexed keywords

CHOLERA TOXIN; DNA VACCINE; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PROTOZOAL VACCINE; RECOMBINANT PROTEIN; RON4 PROTEIN; RON4S2 PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGENICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; EMBRYO; FEMALE; GENE EXPRESSION SYSTEM; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; INSECT CELL; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TOXOPLASMA GONDII; TOXOPLASMOSIS; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, PROTOZOAN; CELL LINE; CYTOKINES; DROSOPHILA; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED CBA; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; VACCINES, DNA;

EID: 82455209004     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.099     Document Type: Article

References (48)

1. Innes E.A. Vaccination against Toxoplasma gondii: an increasing priority for collaborative research?. Expert Rev Vaccines 2010, 9(October (10)):1117-1119.
2. Coombs G.H., Muller S. Recent advances in the search for new anti-coccidial drugs. Int J Parasitol 2002, 32(May (5)):497-508.
3. Innes E.A., Vermeulen A.N. Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma and Neospora. Parasitology 2006, 133(Suppl.):S145-S168.
4. Jongert E., Roberts C.W., Gargano N., Forster-Waldl E., Petersen E. Vaccines against Toxoplasma gondii: challenges and opportunities. Mem Inst Oswaldo Cruz 2009, 104(March (2)):252-266.
5. Dlugonska H. Toxoplasma rhoptries: unique secretory organelles and source of promising vaccine proteins for immunoprevention of toxoplasmosis. J Biomed Biotechnol 2008, 2008:632424.
6. Dziadek B., Gatkowska J., Brzostek A., Dziadek J., Dzitko K., Dlugonska H. Toxoplasma gondii: the immunogenic and protective efficacy of recombinant ROP2 and ROP4 rhoptry proteins in murine experimental toxoplasmosis. Exp Parasitol 2009, 123(September (1)):81-89.
7. Yuan Z.G., Zhang X.X., Lin R.Q., Petersen E., He S., Yu M., et al. Protective effect against toxoplasmosis in mice induced by DNA immunization with gene encoding Toxoplasma gondii ROP18. Vaccine 2011, 29(September (38)):6614-6619.
8. Garcia J.L., Gennari S.M., Navarro I.T., Machado R.Z., Sinhorini I.L., Freire R.L., et al. Partial protection against tissue cysts formation in pigs vaccinated with crude rhoptry proteins of Toxoplasma gondii. Vet Parasitol 2005, 129(May (3-4)):209-217.
9. Garcia J.L., Navarro I.T., Biazzono L., Freire R.L., da Silva Guimaraes Junior J., Cryssafidis A.L., et al. Protective activity against oocyst shedding in cats vaccinated with crude rhoptry proteins of the Toxoplasma gondii by the intranasal route. Vet Parasitol 2007, 145(April (3-4)):197-206.
10. Bradley P.J., Ward C., Cheng S.J., Alexander D.L., Coller S., Coombs G.H., et al. Proteomic analysis of rhoptry organelles reveals many novel constituents for host-parasite interactions in Toxoplasma gondii. J Biol Chem 2005, 280(October (40)):34245-34258.
11. Alexander D.L., Mital J., Ward G.E., Bradley P., Boothroyd J.C. Identification of the moving junction complex of Toxoplasma gondii: a collaboration between distinct secretory organelles. PLoS Pathog 2005, 1(October (2)):e17.
12. Besteiro S., Michelin A., Poncet J., Dubremetz J.F., Lebrun M. Export of a Toxoplasma gondii rhoptry neck protein complex at the host cell membrane to form the moving junction during invasion. PLoS Pathog 2009, 5(February (2)):e1000309.
13. Lamarque M., Besteiro S., Papoin J., Roques M., Vulliez-Le Normand B., Morlon-Guyot J., et al. The RON2-AMA1 interaction is a critical step in moving junction-dependent invasion by apicomplexan parasites. PLoS Pathog 2011, 7(February (2)):e1001276.
14. Remarque E.J., Faber B.W., Kocken C.H., Thomas A.W. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 2008, 24(February (2)):74-84.
15. Dautu G., Munyaka B., Carmen G., Zhang G., Omata Y., Xuenan X., et al. Toxoplasma gondii: DNA vaccination with genes encoding antigens MIC2, M2AP, AMA1 and BAG1 and evaluation of their immunogenic potential. Exp Parasitol 2007, 116(July (3)):273-282.
16. Narum D.L., Nguyen V., Zhang Y., Glen J., Shimp R.L., Lambert L., et al. Identification and characterization of the Plasmodium yoelii PyP140/RON4 protein, an orthologue of Toxoplasma gondii RON4, whose cysteine-rich domain does not protect against lethal parasite challenge infection. Infect Immun 2008, 76(November (11)):4876-4882.
17. Liu M.A., Ulmer J.B. Human clinical trials of plasmid DNA vaccines. Adv Genet 2005, 55:25-40.
18. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
19. Mevelec M.N., Bout D., Desolme B., Marchand H., Magne R., Bruneel O., et al. Evaluation of protective effect of DNA vaccination with genes encoding antigens GRA4 and SAG1 associated with GM-CSF plasmid, against acute, chronical and congenital toxoplasmosis in mice. Vaccine 2005, 23(August (36)):4489-4499.
20. Ismael A.B., Hedhli D., Cerede O., Lebrun M., Dimier-Poisson I., Mevelec M.N. Further analysis of protection induced by the MIC3 DNA vaccine against T. gondii: CD4 and CD8 T cells are the major effectors of the MIC3 DNA vaccine-induced protection, both Lectin-like and EGF-like domains of MIC3 conferred protection. Vaccine 2009, 27(May (22)):2959-2966.
21. Bonenfant C., Dimier-Poisson I., Velge-Roussel F., Buzoni-Gatel D., Del Giudice G., Rappuoli R., et al. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii. Infect Immun 2001, 69(March (3)):1605-1612.
22. Velge-Roussel F., Marcelo P., Lepage A.C., Buzoni-Gatel D., Bout D.T. Intranasal immunization with Toxoplasma gondii SAG1 induces protective cells into both NALT and GALT compartments. Infect Immun 2000, 68(February (2)):969-972.
23. Lebrun M., Michelin A., El Hajj H., Poncet J., Bradley P.J., Vial H., et al. The rhoptry neck protein RON4 re-localizes at the moving junction during Toxoplasma gondii invasion. Cell Microbiol 2005, 7(December (12)):1823-1833.
24. Khaznadji E., Boulard C., Moire N. Expression of functional hypodermin A, a serine protease from Hypoderma lineatum (Diptera, Oestridae), in Schneider 2 cells. Exp Parasitol 2003, 104(May-June (1-2)):33-39.
25. Leriche M.A., Dubremetz J.F. Characterization of the protein contents of rhoptries and dense granules of Toxoplasma gondii tachyzoites by subcellular fractionation and monoclonal antibodies. Mol Biochem Parasitol 1991, 45(April (2)):249-259.
26. Ismael A.B., Sekkai D., Collin C., Bout D., Mevelec M.N. The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis. Infect Immun 2003, 71(November (11)):6222-6228.
27. Qin H., Cha S.C., Neelapu S.S., Liu C., Wang Y.H., Wei J., et al. Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines. Vaccine 2010, 28(November (50)):7970-7978.
28. Kreiss P., Cameron B., Rangara R., Mailhe P., Aguerre-Charriol O., Airiau M., et al. size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Res 1999, 27(October (19)):3792-3798.
29. Darquet A.M., Cameron B., Wils P., Scherman D., Crouzet J. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther 1997, 4(December (12)):1341-1349.
30. Yin W., Xiang P., Li Q. Investigations of the effect of DNA size in transient transfection assay using dual luciferase system. Anal Biochem 2005, 346(November (2)):289-294.
31. Hirata K., Nishikawa M., Kobayashi N., Takahashi Y., Takakura Y. Design of PCR-amplified DNA fragments for in vivo gene delivery: size-dependency on stability and transgene expression. J Pharm Sci 2007, 96(September (9)):2251-2261.
32. Schirmbeck R., Konig-Merediz S.A., Riedl P., Kwissa M., Sack F., Schroff M., et al. Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide. J Mol Med (Berl) 2001, 79(June (5-6)):343-350.
33. Liu M.A. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011, 239(January (1)):62-84.
34. Nielsen M., Lundegaard C., Worning P., Lauemoller S.L., Lamberth K., Buus S., et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003, 12(May (5)):1007-1017.
35. Buus S., Lauemoller S.L., Worning P., Kesmir C., Frimurer T., Corbet S., et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens 2003, 62(November (5)):378-384.
36. Debard N., Buzoni-Gatel D., Bout D. Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. Infect Immun 1996, 64(June (6)):2158-2166.
37. Igarashi M., Kano F., Tamekuni K., Machado R.Z., Navarro I.T., Vidotto O., et al. Toxoplasma gondii: evaluation of an intranasal vaccine using recombinant proteins against brain cyst formation in BALB/c mice. Exp Parasitol 2008, 118(March (3)):386-392.
38. Kang H., Remington J.S., Suzuki Y. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase. J Immunol 2000, 164(March (5)):2629-2634.
39. Sayles P.C., Gibson G.W., Johnson L.L. B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infect Immun 2000, 68(March (3)):1026-1033.
40. Letscher-Bru V., Villard O., Risse B., Zauke M., Klein J.P., Kien T.T. Protective effect of vaccination with a combination of recombinant surface antigen 1 and interleukin-12 against toxoplasmosis in mice. Infect Immun 1998, 66(September (90)):4503-4506.
41. Vercammen M., Scorza T., Huygen K., De Braekeleer J., Diet R., Jacobs D., et al. DNA vaccination with genes encoding Toxoplasma gondii antigens GRA1, GRA7, and ROP2 induces partially protective immunity against lethal challenge in mice. Infect Immun 2000, 68(January (1)):38-45.
42. Martin V., Supanitsky A., Echeverria P.C., Litwin S., Tanos T., De Roodt A.R., et al. Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis. Clin Diagn Lab Immunol 2004, 11(July (4)):704-710.
43. Nielsen H.V., Di Cristina M., Beghetto E., Spadoni A., Petersen E., Gargano N. Toxoplasma gondii: DNA vaccination with bradyzoite antigens induces protective immunity in mice against oral infection with parasite cysts. Exp Parasitol 2006, 112(April (4)):274-279.
44. Echeverria P.C., de Miguel N., Costas M., Angel S.O. Potent antigen-specific immunity to Toxoplasma gondii in adjuvant-free vaccination system using Rop2-Leishmania infantum Hsp83 fusion protein. Vaccine 2006, 24(May (19)):4102-4110.
45. Jongert E., de Craeye S., Dewit J., Huygen K. GRA7 provides protective immunity in cocktail DNA vaccines against Toxoplasma gondii. Parasite Immunol 2007, 29(September (9)):445-453.
46. Cuppari A.F., Sanchez V., Ledesma B., Frank F.M., Goldman A., Angel S.O., et al. Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis. Vaccine 2008, 26(September (39)):5040-5045.
47. Hedhli D., Dimier-Poisson I., Judge J.W., Rosenberg B., Mevelec M.N. Protective immunity against Toxoplasma challenge in mice by coadministration of T. gondii antigens and Eimeria profilin-like protein as an adjuvant. Vaccine 2009, 27(April (16)):2274-2281.
48. Sanchez V.R., Pitkowski M.N., Fernandez Cuppari A.V., Rodriguez F.M., Fenoy I.M., Frank F.M., et al. Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection. Exp Parasitol 2011, 128(August (4)):448-453.